Fresh analysis reveals that people who stop using popular weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass far faster than those who stop traditional diet and exercise programs.
Findings released in a prominent medical journal shows that while obese people often shed substantial amounts of their body weight while on the medication, the mass returns at an average rate of nearly a kilo each month upon discontinuation.
"Individuals purchasing such drugs need to be informed of the danger of fast weight regain when the treatment concludes," stated lead investigator Dr. Susan Jebb.
That rate of regain suggests a return to pre-treatment weight in about one and a half years.
Analyzing Approaches
The analysis, which looked at 37 of trials involving thousands of participants, contrasted the outcomes of GLP-1 agonists with other pills.
The team emphasize that people who shed pounds through lifestyle changes alone usually have a less rapid weight regain—perhaps 100 grams monthly—post-intervention.
Explaining the Rapid Rebound
Experts suggest the mechanism of the injections accounts for the accelerated weight return.
GLP-1 drugs copy a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Long-term administration of the hormone concentrations far above than normal may cause the system to produce less of its endogenous GLP-1, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this hormone supplement leads to appetite is uncontrolled, making excessive eating a significant risk."
A Lifelong Issue?
Medical guidelines advise the jabs for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Many experts argue that, due to the likelihood of weight regain, the therapy is often ongoing.
This opinion is reinforced by pharmaceutical companies, who note that the findings "underscore the persistent character of obesity," similar to managing conditions like hypertension.
User Accounts
People who have stopped the jabs explain a intense resurgence of appetite.
"I experienced a switch flipping and I was suddenly ravenous," described one woman.
The struggle is compounded if individuals have not established permanent dietary or behavioural changes during therapy.
Significant Interest
Survey data indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Use is greater among women than males.
- The middle-aged demographic shows the highest usage rates.
- Many access the medications through private healthcare rather than public health services.
Ultimately, experts caution that while GLP-1 drugs are effective agents for weight loss, they are not a permanent fix and long-term success likely depends on ongoing behavioural management.
